News Releases

Sensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron’s Libtayo®

Sep 27, 2023

Sensei Biotherapeutics Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference

Sep 21, 2023

Sensei Biotherapeutics to Present New Preclinical Data Supporting Mechanism of Action, Pharmacokinetic Profile and Safety Characteristics for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Seventh CRI-ENCI-AACR International Cancer Immuno

Sep 13, 2023

Sensei Biotherapeutics to Participate in Upcoming Investor Conferences

Aug 30, 2023

Sensei Biotherapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Aug 03, 2023

Sensei Biotherapeutics to Participate in Canaccord Genuity’s 43rd Annual Growth Conference

Aug 02, 2023

Sensei Biotherapeutics to Host Virtual Key Opinion Leader Event, “A New Vista for Cancer Care: Exploring SNS-101’s Potential as a Transformative Treatment Option for Patients with Solid Tumors”

Jun 13, 2023

Sensei Biotherapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of SNS-101, a Conditionally Active VISTA-blocking Antibody, for the Treatment of Advanced Solid Tumors

Jun 01, 2023

Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference

May 31, 2023

Sensei Biotherapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights

May 09, 2023

Displaying 1 - 10 of 24

HQ: 1405 Research Blvd, Suite 125, Rockville, MD 20850

MA: 22 Boston Wharf Rd, 7th Floor,
Boston, MA 02210